Published in Alzheimers Res Ther on November 30, 2010
NOTCH inhibits osteoblast formation in inflammatory arthritis via noncanonical NF-κB. J Clin Invest (2014) 0.96
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Alzheimer's disease. N Engl J Med (2010) 13.13
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Alzheimer's disease. Lancet (2006) 9.15
Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res (2009) 7.83
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6.55
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 3.95
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Changing face of microglia. Science (2010) 2.79
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Role of toll-like receptor signalling in Abeta uptake and clearance. Brain (2006) 2.70
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol (2008) 2.25
Biomarkers and surrogate markers: an FDA perspective. NeuroRx (2004) 2.20
A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry (2010) 2.06
Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA (1999) 1.98
High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J (2010) 1.91
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol (2006) 1.79
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem (1989) 1.71
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 1.56
A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2009) 1.52
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
Neurochemical aftermath of amateur boxing. Arch Neurol (2006) 1.47
Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther (2004) 1.25
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets (2010) 1.21
The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience (1997) 1.21
Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol (2005) 1.20
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther (2010) 1.17
First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther (2008) 1.16
Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.09
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry (2010) 1.06
Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology (2005) 0.98
Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett (2004) 0.95
Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein. Aging Clin Exp Res (2009) 0.85
Future screening for incipient Alzheimer's disease--the influence of prevalence on test performance. Eur Neurol (2009) 0.85
How can we recognize "disease modification" effects? J Nutr Health Aging (2009) 0.85
Plasma chitotriosidase in health and pathology. Clin Lab (2007) 0.82
The uses of biomarkers in drug development. Ann N Y Acad Sci (2009) 0.82
Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark Med (2010) 0.80
Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology. J Alzheimers Dis (2009) 0.80
Tarenflurbil: mechanisms and myths. Arch Neurol (2010) 0.78
Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease. Scand J Clin Lab Invest (2009) 0.76
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem (2004) 4.23
An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med (2003) 4.20
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement (2007) 3.75
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol (2014) 3.29
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry (2006) 2.39
The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem (2008) 2.35
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord (2007) 2.15
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One (2010) 1.94
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord (2003) 1.77
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol (2009) 1.75
Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet (2002) 1.73
Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res (2003) 1.70
Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry (2012) 1.66
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2007) 1.61
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett (2008) 1.60
Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol (2013) 1.60
Interaction of apolipoprotein E genotype with smoking and physical inactivity on coronary heart disease risk in men and women. Atherosclerosis (2011) 1.58
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Apolipoprotein E polymorphisms in patients with primary open-angle glaucoma. Am J Ophthalmol (2007) 1.56
Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging (2002) 1.56
Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett (2003) 1.55
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis (2007) 1.54
Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery. Ann Thorac Surg (2012) 1.53
Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem (2012) 1.52
A novel pathway for amyloid precursor protein processing. Neurobiol Aging (2009) 1.52
Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res (2007) 1.51
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
Neurochemical aftermath of amateur boxing. Arch Neurol (2006) 1.47
Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol (2009) 1.47
Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol (2010) 1.46
Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener (2013) 1.44
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol (2013) 1.43
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry (2012) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry (2007) 1.38
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol (2007) 1.36
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain (2015) 1.36
Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport (2002) 1.35
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol (2010) 1.35
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol (2012) 1.33
TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. Neurodegener Dis (2005) 1.33
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation (2012) 1.31
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 1.30
Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett (2003) 1.29
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res (2006) 1.27
Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid. Proc Natl Acad Sci U S A (2011) 1.27
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg (2005) 1.25
CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One (2012) 1.25
Plasma Abeta in Alzheimer's disease--up or down? Lancet Neurol (2006) 1.24
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int (2006) 1.24
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement Geriatr Cogn Disord (2009) 1.23
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res (2010) 1.22
Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging (2007) 1.21
Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain (2008) 1.20
Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment. Dement Geriatr Cogn Disord (2003) 1.20
Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology (2013) 1.20
Amyloid beta and APP as biomarkers for Alzheimer's disease. Exp Gerontol (2009) 1.19
The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry (2007) 1.18
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease. Alzheimers Res Ther (2010) 1.17
Monitoring of brain interstitial total tau and beta amyloid proteins by microdialysis in patients with traumatic brain injury. J Neurosurg (2009) 1.17
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol (2005) 1.16
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med (2006) 1.15